TAGCyx is pursuing collaborative research with HEALIOS K.K. (CEO: Hardy TS Kagimoto, MD, Head office: Tokyo, listed on Tokyo Stock Exchange Mothers Index: 4593) to generate innovative DNA aptamers for use in regenerative medicine using TAGCyx’ proprietary Xenoligo® platform. We are pleased to disclose that we have reached a milestone in the collaboration and received the relevant milestone payment.
Due to confidentiality obligations in our agreement with Healios, further details are not disclosed.
TAGCyx has signed a collaborative research agreement with GlyTech, Inc. (CEO: Hiroaki Asai, Head office: Kyoto) in relation to glycosylation techniques for aptamer therapeutics.
TAGCyx possesses a leading, proprietary, artificial nucleic acid base pair technology, used to produce high affinity and selective “Xenoligo®” DNA aptamers, while GlyTech possesses a unique platform for the production of an extensive variety of highly purified human N-glycans, and the technology to attach them to a specific site on target molecules such as synthetic peptides.
Modifying Xenoligo® with GlyTech’s glycosylation technology is expected to increase the functionality of aptamers and add high value to them.
Dr Chizuko Koseki, Chief Executive Officer of TAGCyx added “We are pleased to enter into a collaboration with GlyTech, bringing together two leading technologies to potentially enhance therapeutics research”.
TAGCyx has signed collaborative research agreement with Chiome Bioscience Inc. (CEO: Shigeru Kobayashi, Head office: Tokyo, listed on Tokyo Stock Exchange Mothers Index: 4583) in relation to innovative aptamer therapeutics.
TAGCyx possesses a leading, proprietary, artificial nucleic acid base pair technology (Xenoligo), producing high affinity and selective DNA aptamers “Xenoligo®”, whereas Chiome is pursuing development of unique therapeutic monoclonal antibody(ies).
Conjugating Xenoligo with Chiome’s monoclonal antibodies will generate bispecific molecules that have the potential to further enhance the functionality of potential therapeutic agents.
Dr Chizuko Koseki, Chief Executive Officer of TAGCyx added “we are pleased to enter into a collaboration with Chiome, bringing together 2 leading technologies to potentially enhance therapeutic research”
TAGCyx will organize “Aptamer Seminar in Tokyo” on October 4th 2019.
Aptamer Seminar in Tokyo
4th October 2019 (Friday) 13:00-19:00
TKP Tokyo Station Nihonbashi Conference Centre、Room 218
〒103-0028 Tōkyō-to, Chuo City, Yaesu, 1-chōme−2−16 TG Bldg （No parking）
13:00 Opening Remarks (Dr. Koseki)
13:15 Dr. Jean-Jacques Toulmé
Research Director, Emeritus, Inserm; – Scientific Director, Co-founder at Novaptech
“Aptasensing small molecules”
14:05 Dr. Ichiro Hirao
Founder of TAGCyx Biotechnologies Inc.
Covering Executive Director, Team Leader and Principal Research Scientist
Institute of Bioengineering and Nanotechnology, A*STAR (Singapore)
“High-affinity and high-specificity DNA aptamer generation by genetic alphabet expansion”
14:55 Dr. Shinsuke Sando
Professor, Department of Chemistry & Biotechnology, Department of Bioengineering (adjunct), School of Engineering, The University of Tokyo
“Aptamers for controlling cellular functions and fates”
15:45- 16:00 Break time
16:00 Dr. Keitaro Yoshimoto
Associate Prof., PI, Department of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo,
“Magnetic-beads Assisted Capillary Electrophoresis (MACE) for Aptamer Selection”
16:50 Dr. Chizuko Koseki
President and CEO TAGCyx Biotechnologies
“Xenoligo® drug discovery and development using unnatural base pair technology”
17:40 Closing remarks
17:50 -19:00 Networking
Registration fee: 1000 JPY/person